If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 62.50
Bid: 60.00
Ask: 65.00
Change: 0.00 (0.00%)
Spread: 5.00 (8.333%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 62.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wanda Expanding to Orthopedic Analytics

19 Mar 2018 07:00

RNS Number : 0704I
NetScientific PLC
19 March 2018
 

 

Health Resource Solutions ("HRS") is expanding utilization of Wanda's Telehealth and Predictive Analytics to Orthopedics

 

London, UK - March 19th 2017 - NetScientific plc ("NetScientific", AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that Wanda Health, its portfolio company, is expanding into orthopedics through a new partnership with HRS Home Health ("HRS").

 

Wanda's predictive analytics and artificial intelligence solutions already provide remote management solutions for chronic conditions in heart and respiratory health. The partnership with HRS, a Wanda client, brings Wanda's capabilities to bear on orthopedics, and initial pilot studies have demonstrated a decrease in the length of time patients were required to remain in hospital through the use of Wanda's technology. HRS will use Wanda Telehealth and Predictive Analytics to provide real-time data and informatics to orthopedic surgeons and their clinical teams.

 

HRS Home Health partnered with orthopedic surgeons in Omaha, Nebraska to collect metrics in patients' homes that track patient outcomes post-surgery. HRS identified gaps in clinical information that were not being reported to the surgeons and their clinical teams during the critical time frame from 3 to 14 days of post-operative care. To improve patient outcomes, five key metrics were identified for remote telehealth data collection to assist with real time clinical oversight: Knee Flexion, Knee Extension, Pain with Activity, Knee Circumference, and Quadriceps Strength.

 

Initial pilot results demonstrated a decrease in cost per case of 18% compared to cases not involved in the pilot. Initial pilot cases show a decrease in length of stay (LOS) from 19.4 days to 11.5 days. These patients achieved desired outcomes 41% quicker than prior to the pilot. The integration of Wanda's technology with HRS care interventions has decreased readmissions, LOS and cost of care.

 

Commenting on the news, NetScientific's Chief Executive Officer and Chairman of Wanda, Francois R. Martelet said: "We are delighted to announce that Wanda is expanding its analytical focus to orthpedics, which demonstrates the flexibility and potential of the technology. In particular, we are pleased that the initial pilot cases demonstrate a decrease in length of stay (LOS) from 19.4 days to 11.5 days, achieving desired outcomes for patients 41% quicker when using Wanda technology."

 

NetScientific holds a 61.8% stake on a fully diluted basis in Wanda.

 

For more information, please contact:

 

  NetScientific

François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO

Tel: +44 (0)20 3514 1800

 

Consilium Strategic Communications

Mary-Jane Elliott Jessica Hodgson /

Chris Welsh / Laura Thornton

 

 

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com

Stifel Nicolaus Europe Limited (NOMAD and Broker)

Jonathan Senior / David Arch / Ben Maddison

 Tel: +44 (0) 20 7710 7600

 

 

About NetScientific

 

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net

 

 

Health Resource Solutions is expanding utilization of Wanda's Telehealth and Predictive Analytics to Orthopedics

March 15th 2018

Health Resource Solutions (HRS) is expanding their use of Wanda Telehealth and Predictive Analytics to provide real time data and informatics to orthopedic surgeons and their clinical teams.

 

Health Resource Solutions (HRS) is expanding their use of Wanda Telehealth and Predictive Analytics to provide real time data and informatics to orthopedic surgeons and their clinical teams. HRS Home Health partnered with orthopedic surgeons in Omaha, Nebraska to collect metrics in the patient's home that track patient outcomes post-surgery. HRS identified gaps in clinical information that were not being reported to the surgeons and their clinical teams during the critical time frame from 3 to 14 days of post-operative care. To improve patient outcomes, five key metrics were identified for remote telehealth data collection to assist with real time clinical oversight: Knee Flexion, Knee Extension, Pain with Activity, Knee Circumference, and Quadriceps Strength. Initial pilot results demonstrated a decrease in cost per case of 18% compared to cases not involved in the pilot. Initial pilot cases show a decrease in length of stay (LOS) from 19.4 days to 11.5 days. These patients achieved desired outcomes 41% quicker than prior to the pilot. The integration of Wanda's technology with HRS care interventions has decreased readmissions, LOS and cost of care.

 

Furthermore, HRS and Wanda developed a patient friendly daily assessment tool in unison with the clinical tool to maintain a strong focus on individual patient experience. The assessment tool allows patients the ability to communicate remotely with their physician and care team. The following information is collected via HIPAA compliant messages to gage patient experience for possible intervention and prevention techniques: Health Zone (Green, Yellow, Red), Calf/Leg Pain (Yes/No), Following Medication (Yes/No), Fever (Yes/No).

 

Robert Mikulak, Managing Partner and CSO for HRS, noted: "We are very excited by the results we were able to achieve for the patients participating in the Tele-Ortho pilot. A high level of clinical oversight combined with integrated network collaboration has improved clinical outcomes and cost savings for the Patient, Accountable Care Organization (ACO) and The Comprehensive Care for Joint Replacement Program (CJR). Wanda has enabled us to deliver better care, by creating transparency of data for the Surgeons and clinical teams. This allows everyone along the care continuum to make more informed decisions for patients during the recovery process at home. By combining our services with technology and analytics, we are able to provide the right type of care in the right place at the lowest cost.

 

"It is extremely exciting to see how HRS is utilizing Wanda's technology to achieve such improved outcomes. We continuously work toward advancing our offerings in close collaboration with HRS to enable better patient engagement coupled with new insights into health status trajectory of patients. Human-centered technology is once again proven to be one of the key elements in quality driven modern health care." Said Wanda CEO Foad Dabiri.

 

HRS is the largest privately owned high-tech nursing and rehabilitation home health agency in Chicago, IL. HRS recently opened an agency in Omaha, NE to service patients in Omaha and Lincoln, NE. Since 2005, HRS has integrated data and technologies with home health services to measure and increase outcomes and value for patients, caregivers and clinicians. More information about HRS can be found at http://www.healthrs.net and http://www.hrsnebraska.com

 

Wanda is dedicated to advancing the effectiveness and efficiency of medicine by using machine learning and modern software applications, enabling care providers to intelligently monitor, communicate with and manage their patients leading to improved outcomes and efficiencies. More information about Wanda can be found at http://www.yourwanda.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAGGGDXCSBBGIC
Date   Source Headline
15th Apr 20247:00 amRNSProAxsis secures c.£1.8mn investment
27th Mar 20241:34 pmRNSPDS Strategy Update and 2023 Financial Results
13th Mar 20247:00 amRNSBusiness Update
5th Feb 20247:00 amRNSExercise of Options and Issue of Shares
23rd Jan 20247:00 amRNSGlycotest secures $1 million investment
1st Dec 20237:00 amRNSDeepTech Recycling secures £1 million investment
14th Nov 20234:39 pmRNSPDS BioTechnology: Third Quarter Results
13th Nov 20237:00 amRNSDirector/PDMR Shareholding
9th Nov 20235:28 pmRNSPDS Biotech Announces Updated Survival Data
6th Nov 20237:00 amRNSVentive secures c.£900,000 investment
2nd Nov 20237:00 amRNSChange of Adviser
23rd Oct 20236:22 pmRNSPDS Preliminary Biomarker Study Results
13th Oct 20237:00 amRNSExercise of Options
3rd Oct 20234:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20233:21 pmRNSPDS: Interim 24-month survival rate of 74% update
3rd Oct 20237:00 amRNSPDS Biotech: new data on PDS0101
28th Sep 20237:00 amRNSInterim Results
13th Sep 20237:00 amRNSQ-Bot: £3.5 million investment to drive expansion
14th Aug 20235:55 pmRNSPDS Biotech: 2nd Quarter Results, Business Update
14th Aug 20235:51 pmRNSPDS Biotech: Submission of Phase 3 Protocol to FDA
3rd Jul 20237:00 amRNSGrant of Options, Issue of Shares, Director/PDMR
30th Jun 20237:00 amRNSDName-iT Holdings Limited Fundraising
29th Jun 202311:04 amRNSResult of AGM & Board Changes
22nd Jun 20237:00 amRNSVortex Fundraising
14th Jun 20233:31 pmRNSPDS Announces Achievement of Efficacy Threshold
7th Jun 20237:00 amRNSDirector/PDMR Shareholding
6th Jun 20237:00 amRNSNotice of AGM
31st May 20237:01 amRNSPreliminary Results for the year ended 31 Dec 2022
31st May 20237:00 amRNSBoard Changes
26th May 20239:39 amRNSPDS Biotech Announces Interim Data
24th May 20237:00 amRNSSofant and Inmarsat announce joint development
15th May 20233:16 pmRNSPDS Business Update and First Quarter Results
2nd May 20237:00 amRNSGlycotest, Inc. Fundraising
3rd Apr 20237:00 amRNSBusiness Update
30th Mar 20233:51 pmRNSPDS Update
28th Mar 20233:50 pmRNSPDS Business Update and 2022 Financial Results
28th Feb 20237:00 amRNSRelated party loan to ProAxsis Limited
27th Feb 20233:28 pmRNSPDS completes FDA meeting for triple combination
10th Feb 20232:05 pmRNSSecond Price Monitoring Extn
10th Feb 20232:00 pmRNSPrice Monitoring Extension
10th Feb 202311:05 amRNSSecond Price Monitoring Extn
10th Feb 202311:00 amRNSPrice Monitoring Extension
1st Feb 20237:00 amRNSBoard Change
3rd Jan 20231:31 pmRNSPDS Announces Exclusive Global License Agreement
28th Dec 20223:05 pmRNSPDS Biotech: Median Overall Survival announcement
16th Dec 20227:00 amRNSPDS: HPV16 Head and Neck Cancer announcement
12th Dec 20222:00 pmRNSBoard Changes; Options; Co-Investment Agreement
29th Nov 20227:00 amRNSEMV C leads £4.2m round in 5G and SATCOM leader
14th Nov 20222:50 pmRNSPDS Q3 Results and Business Update
14th Nov 20222:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.